Get the Stockscreener App
15.40
1.12%
0.17
Pre-market:
15.40
Trevi Therapeutics Inc stock is traded at $15.40, with a volume of 3.82M.
It is up +1.12% in the last 24 hours and up +45.15% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.
See More
Previous Close:
$15.23
Open:
$15.22
24h Volume:
3.82M
Relative Volume:
2.61
Market Cap:
$1.98B
Revenue:
-
Net Income/Loss:
$-42.76M
P/E Ratio:
-48.00
EPS:
-0.3208
Net Cash Flow:
$-42.09M
1W Performance:
+15.53%
1M Performance:
+45.15%
6M Performance:
+44.06%
1Y Performance:
+153.71%
1-Day Range:
$15.05
$16.12
1-Week Range:
$13.22
$16.12
52-Week Range:
$5.3801
$16.12
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
15.40 | 1.96B | 0 | -42.76M | -42.09M | -0.3208 |
VRTX
Vertex Pharmaceuticals Inc
|
439.18 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.41 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
834.45 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.94 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
318.07 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Initiated | Morgan Stanley | Overweight |
| Jul-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics Closes $173 Million Share Offering - marketscreener.com
Trevi Therapeutics announces closing of $173 million underwritten offering - marketscreener.com
Trevi Therapeutics Announces Closing Of $173 Million Underwritten Offering - TradingView
Trevi brings in $173M after underwriters buy all extra shares - Stock Titan
TRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happening - MSN
Can Trevi Therapeutics Address The Big Unmet Need In Chronic Cough? - RTTNews
Trevi Therapeutics launches $150M public stock offering - MSN
What's Going On With Trevi Therapeutics Stock? - Sahm
Netflix, Trevi Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
TRVI Maintains Buy Rating by D. Boral Capital -- Price Target Un - GuruFocus
Trevi Therapeutics Inc (TRVI) Stock Price, Quote, News & History - Benzinga
Trevi Therapeutics (NASDAQ: TRVI) raises ~$150.8M via 11.6M shares - Stock Titan
TRVI Stock’s Five-Day Rally Pushes It To An All-Time High – Here’s What’s Happening - Stocktwits
D. Boral Capital Reiterates "Buy" Rating for Trevi Therapeutics (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics: Late-Stage Transition Meets Execution Risk (NASDAQ:TRVI) - Seeking Alpha
Trevi Therapeutics (NASDAQ:TRVI) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
TRVI: Key Developments in Recent Offering - GuruFocus
New Haven’s Trevi Therapeutics plans $150M stock offering to fund late-stage drug trials - Hartford Business Journal
Trevi Therapeutics Prices Public Offering to Fund Haduvio - TipRanks
Trevi Therapeutics (NASDAQ: TRVI) raises $150M in stock sale - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Trevi Therapeutics Prices $150 Million Common Stock Offering; Shares Down Pre-Bell - marketscreener.com
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Sahm
Trevi sells 11.6M shares at $13, aiming to raise about $150M - Stock Titan
TRVI Forecast, Price Target & Analyst Ratings | TREVI THERAPEUTICS INC (NASDAQ:TRVI) - ChartMill
Trevi Therapeutics Expects Offering to Close on or About April 20 >TRVI - Moomoo
Trevi Therapeutics Prices 11.6M Public Offering Shares at $13 Each >TRVI - Moomoo
Trevi Therapeutics prices $150M stock offering at $13 per share - Investing.com
Trevi Therapeutics, Inc. Prices Underwritten Public Offering of 11.6 Million Shares at $13.00 Each - Quiver Quantitative
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock - The Manila Times
Trevi Therapeutics announces pricing of $150 million underwritten offering of common stock - marketscreener.com
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock - GlobeNewswire Inc.
Trevi Therapeutics launches $150M public stock offering By Investing.com - Investing.com South Africa
Trevi Therapeutics stock hits all-time high at 14.4 USD By Investing.com - Investing.com India
Trevi Therapeutics announces proposed public offering of common stock - marketscreener.com
Trevi Therapeutics stock tumbles on public offering plan By Investing.com - Investing.com South Africa
Trevi Therapeutics stock tumbles on public offering plan - Investing.com
Trevi Therapeutics (NASDAQ: TRVI) seeks $150M in stock offering; option $22.5M - Stock Titan
Trevi seeks $150M from investors, with option for $22.5M more - Stock Titan
Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week HighTime to Buy? - MarketBeat
Trevi Therapeutics stock hits all-time high at 14.4 USD - Investing.com
Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Inflation Data: Is Trevi Therapeutics Inc a top pick in the sectorChart Signals & Safe Entry Trade Reports - baoquankhu1.vn
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 earnings call transcript - MSN
Trevi Therapeutics (TRVI) asks shareholders to approve stock-plan refresh and share increase - Stock Titan
Stock Market Recap: Can Trevi Therapeutics Inc continue delivering strong returns - baoquankhu1.vn
Trevi Therapeutics, Inc. (TRVI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):